Goldman Sachs Group Inc Cardiol Therapeutics Inc. Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
A detailed history of Goldman Sachs Group Inc transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 23,500 shares of CRDL stock, worth $42,300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,500
Previous 23,500
-0.0%
Holding current value
$42,300
Previous $42,000
11.9%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CRDL
# of Institutions
46Shares Held
5.53MCall Options Held
162KPut Options Held
7.4K-
Tejara Capital LTD London, X01.72MShares$3.1 Million1.26% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD1.47MShares$2.64 Million0.55% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9924KShares$1.66 Million0.36% of portfolio
-
Lion Street Advisors, LLC273KShares$491,9050.19% of portfolio
-
Foundations Investment Advisors, LLC162KShares$291,5100.01% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $111M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...